Clinical Trial Update: A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study is evaluating pirtobrutinib for immune thrombocytopenia (ITP). The trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Immune Thrombocytopenia (ITP) | Phase 1, Phase 2 | Status: RECRUITING